In some centers, a strategy of “reflex” testing is followed: patients with adenocarcinoma are tested for the presence of EGFR mutations first and, if negative, they are tested for the presence of KRAS mutations [45] in an effort to obtain information about the driver mutation while saving time, tissue, and resources. The gene discussed is EGFR; the disease is adenocarcinoma.